Spots Global Cancer Trial Database for imbruvica
Every month we try and update this database with for imbruvica cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma | NCT01779791 | Lymphoma | PCI-32765 (Ibru... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | NCT02801578 | Chronic Lymphoc... | Ibrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | NCT02381080 | B-Cell Chronic ... | Ibrutinib Erythromycin Voriconazole | 18 Years - | Janssen Research & Development, LLC | |
| Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | NCT02950038 | Lung Cancer, No... | Ibrutinib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT02780830 | Core: Relapsed ... Module 1: Non-G... | AZD2014 Ibrutinib | 18 Years - 130 Years | AstraZeneca | |
| Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma | NCT02169180 | Lymphoma, Mantl... | Ibrutinib | 20 Years - | Janssen Pharmaceutical K.K. | |
| AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT02780830 | Core: Relapsed ... Module 1: Non-G... | AZD2014 Ibrutinib | 18 Years - 130 Years | AstraZeneca | |
| A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer | NCT02321540 | Lung Cancer | Ibrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | NCT02950038 | Lung Cancer, No... | Ibrutinib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer | NCT02321540 | Lung Cancer | Ibrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma | NCT02169180 | Lymphoma, Mantl... | Ibrutinib | 20 Years - | Janssen Pharmaceutical K.K. | |
| Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma | NCT04477486 | Mantle Cell Lym... | Ibrutinib Venetoclax | 20 Years - | AbbVie | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | NCT03873493 | Leukemia T-cell Prolymph... Cancer | Venetoclax Ibrutinib | 18 Years - | AbbVie | |
| Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma | NCT04477486 | Mantle Cell Lym... | Ibrutinib Venetoclax | 20 Years - | AbbVie | |
| Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | NCT02381080 | B-Cell Chronic ... | Ibrutinib Erythromycin Voriconazole | 18 Years - | Janssen Research & Development, LLC | |
| Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma | NCT02269085 | Lymphoma | Ibrutinib Carfilzomib Phone Calls | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
